JP
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Whitepaper
Ex Vivo Functional Drug Testing of 3D Patient-Derived Cancer Cells Shows Promise for Personalized Medicine
Researchers at the Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, are demonstrating how functional screening of 3D patient-derived cancer cells enables effective drug sensitivity testing and the ability to potentially tailor medicines to an individual patient.
We spoke to a Senior Scientist and Principal Investigator from FIMM, to hear more about their approach. Read the whitepaper to find out what they said.
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
Ex Vivo Functional Drug Testing of 3D Patient-Derived Cancer Cells Shows Promise for Personalized Medicine